BUZZ-BioCryst rises on US FDA approval for oral formulation of rare disease drug

Shares of drugmaker BioCryst Pharmaceuticalsrise 2% to $7.73 premarketUS FDA approves co’s oral pellet formulation of once-daily drug Orladeyo for pediatric patients with hereditary angioedemaHereditary angioedema is a genetic disorder that causes episodes of swelling in different parts of a child’s body, including in the face and handsOrladeyo is a prophylactic therapy designed to prevent attacks of hereditary angioedemaUp to last close, stock up 0.8% YTD